Loading...

ABUS ARBUTUS BIOPHARMA CORP Management Changes 8-K Filing

RBTS

BS

ARBUTUS BIOPHARMA CORP

(ABUS)

2025 8-K

Show Summary

Show Summary

Financial Statements

Presentation of Research Fi...

Conference Presentations

Management Changes

Financial Results

Patent Litigation

Board Restructuring

Financial Update

Clinical Trial Results

Q3 2024 Results

Clinical Data Presentation

Management Change

Regulation FD Disclosure

Financial Results and Corpo...

Clinical Trial Results

Clinical Trial Results

Shareholder Meeting Approval

Announcement of Abstract Ac...

Financial Results and Corpo...

Retirement of Chief Scienti...

Financial Results and Corpo...

Financial Results

Management Changes

Poster Presentation and Cor...

Financial Results, Workforc...

Retirement and Appointment

Announcement of Data Presen...

Pipeline Updates

Financial Results and Corpo...

Clinical Trial Update

Clinical Trial Results

Announcement of Poster Pres...

Management Changes

Financial Results and Corpo...

Clinical Data Presentation

Announcement of Abstract Ac...

Lawsuit against Pfizer and ...

Preclinical Data Announcement

Financial Results and Corpo...

Resignation of Director

External Links:

On May 21, 2025, Arbutus Biopharma Corp held its Annual General Meeting where shareholders elected directors, approved executive compensation, and appointed Ernst & Young as auditors for 2025.

AI Assistant

ARBUTUS BIOPHARMA CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.